Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape

Journal of Infectious Diseases

Volumn 205, Issue 11, 2012, Pages 1757-1761

  Martel, Nora ^a,c   Cotte, Laurent ^a,b   Trabaud, Mary Anne ^b   Trepo, Christian ^a,b   Zoulim, Fabien ^a,b   Gomes, Selma A ^c   Kay, Alan ^a  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b CROIX ROUSSE HOSPITAL   (France)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; EMTRICITABINE; ENFUVIRTIDE; EPITOPE; FLUTICASONE; GLUCOCORTICOID; HEPATITIS B SURFACE ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; RITONAVIR; SALMETEROL; SAQUINAVIR; TENOFOVIR; TRIAMCINOLONE;

ACUTE HEPATITIS; ADULT; ARTICLE; CASE REPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ESCAPE; IMMUNITY; LATENT VIRUS INFECTION; PRIORITY JOURNAL; SEROLOGY; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS REACTIVATION; VIRUS STRAIN;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EPITOPES; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; IMMUNE EVASION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUTATION, MISSENSE; VIRUS ACTIVATION;

EID: 84861083986     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis268     Document Type: Article

References (15)

1. Nowicki MJ, Tong MJ, Nair PV, Stevenson D. Detection of anti-HBc IgM following prednisone treatment in patients with chronic active hepatitis B virus infection. Hepatology 1984; 4:1129-33. (Pubitemid 15192262)
2. Sagnelli E, Manzillo G, Maio G, et al. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; 2:395-7. (Pubitemid 10056533)
3. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167:630-3. (Pubitemid 19037154)
4. Josephson F. Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition. J Intern Med 2010; 268:530-9.
5. Margeridon S, Carrouee-Durantel S, Chemin I, et al. Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA. Antimicrob Agents Chemother 2008; 52:3068-73.
6. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69:5437-44.
7. Jeantet D, Chemin I, Mandrand B, Zoulim F, Trepo C, Kay A. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology 2002; 35:1215-24. (Pubitemid 34454019)
8. Margeridon S, Lachaux A, Trepo C, Zoulim F, Kay A. A quasimonoclonal anti-HBs response can lead to immune escape of "wild-type" hepatitis B virus. J Gen Virol 2005; 86:1687-93. (Pubitemid 40766880)
9. Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Gunther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology 2005; 42:93-103. (Pubitemid 40911316)
10. Lam KC, Lai CL, Ng RP, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. New England Journal of Medicine 1981; 304:380-6. (Pubitemid 11167436)
11. Henke-Gendo C, Amini-Bavil-Olyaee S, Challapalli D, et al. Symptomatic hepatitis B virus (HBV) reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIVcoinfected patient. J Infect Dis 2008; 198:1620-4.
12. Kim KH, Lee KH, Chang HY, et al. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 2003; 71:367-75.
13. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254-63.
14. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47:289-309. (Pubitemid 39541275)
15. Le Bouvier GL, Capper RA, Williams AE, Pelletier M, Katz AJ. Concurrently circulating hepatitis B surface antigen and heterotypic anti-HBs antibody. J Immunol 1976; 117:2262-4. (Pubitemid 8009027)